vs
BioNTech SE（BNTX）与高乐氏（CLX）财务数据对比。点击上方公司名可切换其他公司
高乐氏的季度营收约是BioNTech SE的1.1倍（$1.7B vs $1.5B），高乐氏净利率更高（9.4% vs -1.9%，领先11.3%）
BioNTech SE是总部位于德国美因茨的跨国生物技术企业，专注于免疫疗法及疫苗研发工作，核心研究方向覆盖肿瘤、传染性疾病等医疗领域，相关技术处于全球生物医药行业领先水平。
高乐氏是美国跨国企业，专业从事消费级与专业用途产品的生产及营销。2000年至2024年持续入选《财富》500强榜单，最新排名为第485位，旗下产品覆盖清洁护理、家居日用等多个品类，在全球消费市场拥有较高认可度。
BNTX vs CLX — 直观对比
营收规模更大
CLX
是对方的1.1倍
$1.5B
净利率更高
CLX
高出11.3%
-1.9%
损益表 — Q3 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $1.7B |
| 净利润 | $-28.7M | $157.0M |
| 毛利率 | — | 43.2% |
| 营业利润率 | -3.1% | — |
| 净利率 | -1.9% | 9.4% |
| 营收同比 | — | 0.3% |
| 净利润同比 | — | -15.6% |
| 每股收益（稀释后） | — | $1.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BNTXCLX
| Q4 25 | — | $1.7B | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $260.8M | $2.0B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | $1.2B | $1.8B | ||
| Q2 24 | — | $1.9B | ||
| Q1 24 | — | $1.8B |
净利润BNTXCLX
| Q4 25 | — | $157.0M | ||
| Q3 25 | $-28.7M | — | ||
| Q2 25 | $-386.6M | $332.0M | ||
| Q1 25 | — | $186.0M | ||
| Q4 24 | — | $193.0M | ||
| Q3 24 | $198.1M | $99.0M | ||
| Q2 24 | — | $216.0M | ||
| Q1 24 | — | $-51.0M |
毛利率BNTXCLX
| Q4 25 | — | 43.2% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 46.5% | ||
| Q1 25 | — | 44.6% | ||
| Q4 24 | — | 43.8% | ||
| Q3 24 | — | 45.8% | ||
| Q2 24 | — | 46.5% | ||
| Q1 24 | — | 42.2% |
营业利润率BNTXCLX
| Q4 25 | — | — | ||
| Q3 25 | -3.1% | — | ||
| Q2 25 | -192.1% | 20.6% | ||
| Q1 25 | — | 15.2% | ||
| Q4 24 | — | 14.1% | ||
| Q3 24 | 0.8% | 10.0% | ||
| Q2 24 | — | 14.5% | ||
| Q1 24 | — | -2.3% |
净利率BNTXCLX
| Q4 25 | — | 9.4% | ||
| Q3 25 | -1.9% | — | ||
| Q2 25 | -148.2% | 16.7% | ||
| Q1 25 | — | 11.2% | ||
| Q4 24 | — | 11.4% | ||
| Q3 24 | 15.9% | 5.6% | ||
| Q2 24 | — | 11.4% | ||
| Q1 24 | — | -2.8% |
每股收益（稀释后）BNTXCLX
| Q4 25 | — | $1.29 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $2.68 | ||
| Q1 25 | — | $1.50 | ||
| Q4 24 | — | $1.54 | ||
| Q3 24 | — | $0.80 | ||
| Q2 24 | — | $1.74 | ||
| Q1 24 | — | $-0.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $227.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $-125.0M |
| 总资产 | — | $5.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BNTXCLX
| Q4 25 | — | $227.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $167.0M | ||
| Q1 25 | — | $226.0M | ||
| Q4 24 | — | $290.0M | ||
| Q3 24 | — | $278.0M | ||
| Q2 24 | — | $202.0M | ||
| Q1 24 | — | $219.0M |
总债务BNTXCLX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | — |
股东权益BNTXCLX
| Q4 25 | — | $-125.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $321.0M | ||
| Q1 25 | — | $27.0M | ||
| Q4 24 | — | $-41.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $328.0M | ||
| Q1 24 | — | $91.0M |
总资产BNTXCLX
| Q4 25 | — | $5.6B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $5.6B | ||
| Q1 25 | — | $5.5B | ||
| Q4 24 | — | $5.6B | ||
| Q3 24 | — | $5.5B | ||
| Q2 24 | — | $5.8B | ||
| Q1 24 | — | $5.8B |
负债/权益比BNTXCLX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 7.74× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 7.56× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BNTX
暂无分部数据
CLX
| Health And Wellness | $643.0M | 38% |
| Household | $419.0M | 25% |
| Lifestyle | $321.0M | 19% |
| Other | $290.0M | 17% |
